Overview
Bedfont Scientific Ltd. is a British multi-award-winning company renowned for manufacturing the NObreath® FeNO monitor, which revolutionized asthma diagnostics and patient monitoring by measuring airway inflammation.
The company is celebrated for transforming standard respiratory care through non-invasive breath analysis, which is recommended by the UK’s National Institute for Health and Care Excellence (NICE).
To explore their breath analysis technology and review their medical devices, visit the Bedfont Scientific platform.
Introduction
I still remember the first time I read about FeNO monitoring in respiratory medicine journals. At first, I was skeptical. Could a simple breath test really help improve asthma diagnosis and long-term disease management? After digging deeper into the science and seeing how healthcare professionals use the technology in real-world clinical settings, it became clear why the respiratory industry considers it such an important breakthrough.
That is exactly why the 10-year milestone celebration of the NObreath® FeNO monitor at the European Respiratory Society (ERS) Congress attracted so much attention across the respiratory healthcare world.
Developed by Bedfont Scientific Ltd, the NObreath® FeNO monitor has spent more than a decade helping clinicians measure airway inflammation quickly, non-invasively, and more affordably than many traditional respiratory diagnostic methods.
At the world-renowned ERS Congress 2017 in Milan, the company celebrated 10 years of innovation in asthma management while showcasing how FeNO measurements continue to shape modern respiratory medicine.
In this article, I’ll break down:
- What FeNO monitoring actually is
- Why respiratory specialists value it
- How the NObreath® monitor works
- Why the technology matters for asthma diagnosis
- How Bedfont became a trusted name in respiratory healthcare
- What healthcare professionals can learn from the ERS event
What Is the NObreath FeNO Monitor?
The NObreath FeNO Monitor is a medical device designed to measure Fractional Exhaled Nitric Oxide, commonly called FeNO.
In simple terms, the device measures the amount of nitric oxide present in a patient’s breath. Elevated FeNO levels are strongly linked to airway inflammation, which is one of the key indicators of certain forms of asthma.
This makes FeNO testing an extremely useful tool for:
- Asthma diagnosis
- Monitoring airway inflammation
- Evaluating treatment effectiveness
- Assessing medication adherence
- Distinguishing allergic asthma from non-allergic asthma
What impressed me most during my research is how quickly the test can be performed. Unlike some traditional pulmonary diagnostics, FeNO testing is:
- Non-invasive
- Fast
- Comfortable for patients
- Easy for clinicians to administer
That combination is exactly why respiratory professionals continue adopting FeNO monitoring technology in clinics and GP practices worldwide.
Why FeNO Monitoring Changed Asthma Management
The Problem with Traditional Asthma Diagnosis
One issue many clinicians face is that asthma symptoms can overlap with several respiratory conditions. Chronic cough, wheezing, chest tightness, and breathing difficulties do not always point directly to asthma.
In my experience researching respiratory case studies, delayed or incorrect diagnosis remains one of the biggest frustrations for both patients and healthcare providers.
Traditional tests sometimes fail to identify underlying airway inflammation clearly, especially in early-stage or mild asthma cases.
That is where Fractional Exhaled Nitric Oxide testing became such a significant advancement.
Understanding Airway Inflammation
Nitric Oxide is naturally produced in the lungs. Higher nitric oxide levels often indicate inflammation inside the airways.
By measuring these levels, healthcare professionals can gain valuable insight into:
- Respiratory symptoms
- Asthma severity
- Treatment response
- Bronchodilator effectiveness
- Disease progression
This is particularly useful for patients with unexplained coughs or recurring breathing issues.
According to respiratory specialists, FeNO measurements provide a more targeted understanding of inflammation than some conventional asthma tests.
How Bedfont Scientific Ltd. Became a Leader in Respiratory Medicine
Bedfont Scientific Ltd built its reputation around breath analysis technology and respiratory diagnostic innovation.
The company officially launched the NObreath® FeNO monitor during the ERS Congress in 2007 and returned a decade later to celebrate its continued impact on respiratory healthcare.
One thing I noticed while researching the company is how strongly they focus on making advanced respiratory testing more accessible and affordable for everyday clinical practice.
That matters because many healthcare systems struggle with:
- Expensive diagnostic equipment
- Time-consuming respiratory procedures
- Complex patient workflows
- Limited access to specialist testing
The NObreath® monitor addresses those challenges by offering:
- Portable testing
- Quick results
- Simple operation
- Cost-effective monitoring
This helped position the company as a trusted name in pulmonary diagnostics and asthma care.
Why the ERS Congress Matters in Respiratory Healthcare
The European Respiratory Society Congress is considered one of the largest gatherings of respiratory professionals in the world.
Specialists from across the healthcare industry attend to discuss:
- Respiratory medicine advancements
- Pulmonary diagnostics
- Asthma treatment innovations
- Clinical guidelines
- New medical technologies
The 2017 event in Milan became especially meaningful because it marked the 10th anniversary of the NObreath® FeNO monitor.
To celebrate, Bedfont organized an interactive competition where participants could:
- Take a FeNO breath test
- Receive their airway inflammation reading
- Enter a prize draw
- Share results on social media using #knowyourFeNO
From a marketing perspective, this was actually a smart strategy. It educated healthcare professionals while also encouraging hands-on experience with the device.
NICE Recommendations and Clinical Credibility
One major reason FeNO monitoring gained trust in respiratory medicine is because it aligns with recognized clinical guidance.
The NICE recommends FeNO testing for asthma diagnosis and management in suitable clinical settings.
Additionally, the device conforms to guidelines established by the:
- ATS
- ERS
- Respiratory medicine authorities
This clinical backing adds substantial credibility to FeNO technology.
In healthcare, evidence matters. Devices supported by established respiratory guidelines tend to see stronger adoption because clinicians need confidence that diagnostic tools are scientifically validated.
Real-World Clinical Use Cases
Assessing Persistent Cough Symptoms
According to Lois Penhaligan, FeNO breath testing is particularly helpful when evaluating patients with unexplained respiratory symptoms.
For example:
- Persistent dry cough
- Suspected allergic asthma
- Unclear airway inflammation
- Monitoring treatment response
I found this especially interesting because respiratory diseases are often highly individualized. A test that helps personalize asthma management can significantly improve patient outcomes.
Monitoring Medication Adherence
Another underrated benefit involves treatment compliance.
Many asthma patients struggle with:
- Inconsistent inhaler use
- Incorrect medication timing
- Poor long-term adherence
By measuring inflammation levels regularly, clinicians can better determine whether prescribed treatments are actually working.
That means GPs can:
- Adjust medication levels
- Identify ineffective treatment plans
- Improve long-term asthma management
Why Non-Invasive Diagnostics Matter
One of the strongest advantages of FeNO testing is patient comfort.
Compared to more invasive respiratory procedures, the NObreath® monitor offers:
- Simple breathing tests
- Fast analysis
- Minimal patient stress
- Easy repeat monitoring
I personally believe this is where modern respiratory diagnostics are heading — less invasive, faster, and more patient-friendly healthcare technology.
As healthcare systems continue evolving, non-invasive medical devices will likely become even more important in:
- Primary care
- Pulmonary clinics
- Asthma management programs
- Preventative respiratory care
Challenges in Asthma Diagnosis Today
Even with modern tools, asthma diagnosis remains complicated for many healthcare providers.
Common challenges include:
- Misdiagnosis
- Symptom overlap
- Delayed treatment
- Poor medication adherence
- Lack of inflammation monitoring
FeNO monitoring does not replace every traditional respiratory test, but it provides an additional layer of diagnostic clarity that many clinicians find valuable.
That combination of convenience and clinical insight explains why the technology has maintained relevance for more than 10 years.
Quick Tips for Better Asthma Monitoring
If You’re a Healthcare Professional
- Consider combining FeNO measurements with traditional lung function tests
- Use airway inflammation tracking for personalized treatment plans
- Monitor patient adherence regularly
If You’re a Patient
- Track symptoms consistently
- Follow prescribed inhaler routines
- Ask your clinician about FeNO testing options
- Attend regular asthma reviews
FAQs
What does FeNO stand for in asthma testing?
FeNO stands for Fractional Exhaled Nitric Oxide. It measures nitric oxide levels in a patient’s breath to assess airway inflammation associated with asthma.
Is the NObreath® FeNO monitor recommended by healthcare authorities?
Yes. FeNO monitoring is supported by respiratory guidelines and recommended by the NICE for appropriate asthma management scenarios.
Can FeNO testing replace traditional asthma tests?
Not entirely. FeNO testing is typically used alongside conventional respiratory diagnostics to provide additional insight into airway inflammation and asthma management.
Final Thoughts
After researching the respiratory healthcare industry and learning how FeNO technology works in real-world clinical settings, it is easy to understand why the NObreath® FeNO monitor became such a respected innovation.
The 10-year celebration at the ERS Congress was more than just a company milestone. It represented a decade of progress in:
- Asthma diagnosis
- Airway inflammation monitoring
- Non-invasive respiratory testing
- Personalized asthma care
For healthcare professionals, the technology offers practical diagnostic value. For patients, it provides a faster and more comfortable testing experience.
Most importantly, it demonstrates how medical innovation can genuinely improve everyday respiratory care when science, accessibility, and patient-centered design come together
